Varamir
Desk
News
Calendar
Pricing
Saved
Search
tickers or companies
⌘K
Start free
· no card
Sign in
CTMX compared with LLY: revenue, margins and what each company keeps, and the suppliers and customers both name
CTMX
CytomX Therapeutics, Inc.
Change
Mkt cap
Revenue
Revenue
LLY
ELI Lilly & Co
Change
Mkt cap
Revenue
Revenue
vs
Compare
CTMX
CytomX Therapeutics, Inc.
vs
LLY
ELI Lilly & Co
Price
Mkt cap
Revenue
Revenue
Change
Change
Revenue flow
Supply chain
Price
Co-movers
Event sensitivity
Earnings history
Save comparison
Copy link
Revenue flow
Desk
News
Calendar
Saved
Search
Revenue flow
Supply chain
Price
Co-movers
Event sensitivity
Earnings history
Price
Supply-chain overlap
Revenue flow
CTMX: latest quarter is a loss; flow not drawable.
Method
›
Supply-chain overlap
direct ties · both sides
Sources
›
direct ties · both sides
Only CTMX
9
ABBV
AbbVie (formerly ImmunoGen)
supplier
MRK
Merck
supplier
AMGN
Amgen
supplier
BMY
Bristol Myers Squibb
customer
5 more · CTMX chain
›
Shared
0
No shared counterparties.
Only LLY
29
MCK
McKesson
customer
CAH
Cardinal Health
customer
VEEV
Veeva Systems
supplier
UTHR
United Therapeutics
customer
Role chip = supplier or customer
—
= no ticker (unlisted)
Source: SEC EDGAR
25 more · LLY chain
›
Price
rebased to 0%
1D
1W
1M
3M
YTD
1Y
5Y
1D
1W
1M
3M
YTD
1Y
5Y
CTMX, solid
LLY, dashed
CTMX
CytomX Therapeutics, Inc.
Change
2.18
· pre 2.18
· delayed
Mkt cap
$475.0M
Revenue
$1M
Q2 FY26
Revenue
$76M
FY25
LLY
ELI Lilly & Co
Change
1,407.25
· pre 1,425.40
· delayed
Pre-market
Nov 4 '26
delayed
Mkt cap
$1.3T
Revenue
$24.4B
Q3 FY26
Revenue
$65.2B
FY25
vs
Compare
Pre-market
Nov 4 '26
delayed
CTMX
CytomX Therapeutics, Inc.
vs
LLY
ELI Lilly & Co
2.18
pre 2.18
delayed
Price
1,407.25
pre 1,425.40
delayed
$475.0M
Mkt cap
$1.3T
Q2 FY26
$1M
Revenue
$24.4B
Q3 FY26
FY25
$76M
Revenue
$65.2B
FY25
Change
Change
CTMX
2.18
vs
LLY
1,407.25
Pre-market
Nov 4 '26
delayed